Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4,356 JPY | -0.11% | +1.82% | +7.45% |
Sales 2024 * | 4,062B 27.23B | Sales 2025 * | 3,990B 26.75B | Capitalization | 6,842B 45.87B |
---|---|---|---|---|---|
Net income 2024 * | 140B 938M | Net income 2025 * | 236B 1.58B | EV / Sales 2024 * | 2.61 x |
Net Debt 2024 * | 3,763B 25.23B | Net Debt 2025 * | 3,429B 22.99B | EV / Sales 2025 * | 2.57 x |
P/E ratio 2024 * |
47.5
x | P/E ratio 2025 * |
29.2
x | Employees | 49,095 |
Yield 2024 * |
4.31% | Yield 2025 * |
4.35% | Free-Float | 99.11% |
Latest transcript on Takeda Pharmaceutical Company Limited
1 day | +1.37% | ||
1 week | +0.21% | ||
Current month | -0.59% | ||
1 month | -1.16% | ||
3 months | +9.16% | ||
6 months | -10.27% | ||
Current year | +7.57% |
Managers | Title | Age | Since |
---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 57 | 14-03-31 |
Director of Finance/CFO | 52 | 14-12-31 | |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 45 | 22-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 71 | 16-05-31 | |
Ian Clark
BRD | Director/Board Member | 62 | 18-12-31 |
Steven Gillis
BRD | Director/Board Member | 70 | 18-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
24.44% | 14 M€ | +12.18% | ||
3.80% | 1,317 M€ | +16.55% | ||
3.43% | 245 M€ | +13.44% | ||
3.26% | 45 M€ | +19.77% |
Date | Price | Change | Volume |
---|---|---|---|
24-03-18 | 4,356 | -0.11% | 1 553 800 |
24-03-18 | 4,361 | +1.37% | 4,078,300 |
24-03-15 | 4,302 | +0.33% | 5,527,400 |
24-03-14 | 4,288 | +0.33% | 3,947,600 |
24-03-13 | 4,274 | -0.09% | 4,267,700 |
Delayed Quote Japan Exchange, March 18, 2024 at 02:00 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.57% | 45.29B | |
+30.83% | 679B | |
+30.96% | 589B | |
+0.01% | 381B | |
+15.18% | 314B | |
+11.39% | 308B | |
+0.78% | 212B | |
-6.09% | 210B | |
-2.92% | 203B | |
-3.72% | 158B |